{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:07:40Z","timestamp":1791846460217,"version":"4.3.4"},"reference-count":34,"publisher":"Society of Nuclear Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,3,17]]},"published-print":{"date-parts":[[2026,7]]},"DOI":"10.2967\/jnumed.125.271880","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:15:18Z","timestamp":1776870918000},"page":"1109-1116","source":"Crossref","is-referenced-by-count":1,"title":["Phase 1 Dose-Escalation Study of [\n                    <sup>225<\/sup>\n                    Ac]Ac-PSMA I&amp;T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry"],"prefix":"10.2967","volume":"67","author":[{"given":"Sui Wai","family":"Ling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Konijnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Segbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Hooijman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"de Blois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda C.","family":"De Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"van Puffelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quido","family":"de Lussanet de la Sabloniere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bruchertseifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Livia","family":"Chilug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Brabander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2026070106450741000_67.7.1109.1","unstructured":"Prostate cancer factsheet. Global Cancer Observatory: Cancer Today website. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/27-prostate-fact-sheet.pdf. Accessed April 1, 2026."},{"key":"2026070106450741000_67.7.1109.2","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1191"},{"key":"2026070106450741000_67.7.1109.3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13045-020-00978-z","article-title":"Novel therapies are changing treatment paradigms in metastatic prostate cancer","volume":"13","author":"Powers","year":"2020","journal-title":"J Hematol Oncol."},{"key":"2026070106450741000_67.7.1109.4","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.3390\/pharmaceutics14102166","article-title":"Advances in 177Lu-PSMA and 225Ac-PSMA radionuclide therapy for metastatic castration-resistant prostate cancer","volume":"14","author":"Ling","year":"2022","journal-title":"Pharmaceutics."},{"key":"2026070106450741000_67.7.1109.5","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res."},{"key":"2026070106450741000_67.7.1109.6","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3390\/cancers12061367","article-title":"PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy","volume":"12","author":"Jones","year":"2020","journal-title":"Cancers (Basel)."},{"key":"2026070106450741000_67.7.1109.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2007.02635.x"},{"key":"2026070106450741000_67.7.1109.8","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S"},{"key":"2026070106450741000_67.7.1109.9","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2026070106450741000_67.7.1109.10","doi-asserted-by":"crossref","first-page":"102398","DOI":"10.1016\/j.clgc.2025.102398","article-title":"Safety and efficacy of lutetium-177 PSMA therapy for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Belabaci","year":"2025","journal-title":"Clin Genitourin Cancer."},{"key":"2026070106450741000_67.7.1109.11","doi-asserted-by":"publisher","DOI":"10.2174\/1874471011104040306"},{"key":"2026070106450741000_67.7.1109.12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3390\/molecules23030581","article-title":"Progress in targeted alpha-particle therapy. What we learned about recoils release from in\u00a0vivo generators","volume":"23","author":"Kozempel","year":"2018","journal-title":"Molecules."},{"key":"2026070106450741000_67.7.1109.13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12885-024-11900-y","article-title":"Evaluation of the tolerability and safety of [225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study","volume":"24","author":"Ling","year":"2024","journal-title":"BMC Cancer."},{"key":"2026070106450741000_67.7.1109.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.191395"},{"key":"2026070106450741000_67.7.1109.15","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3390\/pharmaceutics13050715","article-title":"Development of [225Ac]Ac-PSMA-I&T for targeted alpha therapy according to GMP guidelines for treatment of mCRPC","volume":"13","author":"Hooijman","year":"2021","journal-title":"Pharmaceutics."},{"key":"2026070106450741000_67.7.1109.16","unstructured":"U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf. Accessed April 1, 2026."},{"key":"2026070106450741000_67.7.1109.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.170720"},{"key":"2026070106450741000_67.7.1109.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1422-4"},{"key":"2026070106450741000_67.7.1109.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2026070106450741000_67.7.1109.20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026070106450741000_67.7.1109.21","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2024.09.020","article-title":"A meta-analysis and meta-regression of the efficacy, toxicity, and quality of life outcomes following prostate-specific membrane antigen radioligand therapy utilising lutetium-177 and actinium-225 in metastatic prostate cancer","volume":"87","author":"Dai","year":"2025","journal-title":"Eur Urol."},{"key":"2026070106450741000_67.7.1109.22","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-021-01617-4"},{"key":"2026070106450741000_67.7.1109.23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/ph8020321","article-title":"A critical review of alpha radionuclide therapy\u2014how to deal with recoiling daughters?","volume":"8","author":"de Kruijff","year":"2015","journal-title":"Pharmaceuticals (Basel)."},{"key":"2026070106450741000_67.7.1109.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.06.090"},{"key":"2026070106450741000_67.7.1109.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.02.089"},{"key":"2026070106450741000_67.7.1109.26","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s13139-019-00589-8","article-title":"Quantitative imaging of alpha-emitting therapeutic radiopharmaceuticals","volume":"53","author":"Seo","year":"2019","journal-title":"Nucl Med Mol Imaging."},{"key":"2026070106450741000_67.7.1109.27","doi-asserted-by":"crossref","unstructured":"Tronchin S Forster JC Hickson K Bezak E . Dosimetry in targeted alpha therapy. A systematic review: current findings and what is needed. Phys Med Biol. 2022;67(9).","DOI":"10.1088\/1361-6560\/ac5fe0"},{"key":"2026070106450741000_67.7.1109.28","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1088\/1361-6560\/aa6a99","article-title":"Multi-isotope SPECT imaging of the 225Ac decay chain: feasibility studies","volume":"62","author":"Robertson","year":"2017","journal-title":"Phys Med Biol."},{"key":"2026070106450741000_67.7.1109.29","doi-asserted-by":"crossref","first-page":"9721","DOI":"10.7150\/thno.63860","article-title":"Practical considerations for quantitative clinical SPECT\/CT imaging of alpha particle emitting radioisotopes","volume":"11","author":"Benabdallah","year":"2021","journal-title":"Theranostics."},{"key":"2026070106450741000_67.7.1109.30","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1007\/s00259-020-05024-1","article-title":"Image-based dosimetry for 225Ac-PSMA-I&T therapy using quantitative SPECT","volume":"48","author":"Gosewisch","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026070106450741000_67.7.1109.31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/ijnm.IJNM_115_18","article-title":"Alpha therapy with 225actinium labeled prostate specific membrane antigen: reporting new photopeak of 78 kilo-electron volts for better image statistics","volume":"34","author":"Rasheed","year":"2019","journal-title":"Indian J Nucl Med."},{"key":"2026070106450741000_67.7.1109.32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/RLU.0000000000002525","article-title":"225Ac prostate-specific membrane antigen posttherapy alpha imaging: comparing 2 and 3 photopeaks","volume":"44","author":"Usmani","year":"2019","journal-title":"Clin Nucl Med."},{"key":"2026070106450741000_67.7.1109.33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/RLU.0000000000003031","article-title":"225Ac-PSMA-617 radioligand posttherapy imaging in metastatic castrate-resistant prostate cancer patient using 3 photopeaks","volume":"45","author":"Vatsa","year":"2020","journal-title":"Clin Nucl Med."},{"key":"2026070106450741000_67.7.1109.34","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3817-y"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.271880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:06:37Z","timestamp":1782914797000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.271880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,1]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.2967\/jnumed.125.271880"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.271880","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]}}}